Sangamo Therapeutics (SGMO) Receivables - Net (2016 - 2025)
Sangamo Therapeutics (SGMO) has 16 years of Receivables - Net data on record, last reported at $523000.0 in Q3 2025.
- For Q3 2025, Receivables - Net fell 95.02% year-over-year to $523000.0; the TTM value through Sep 2025 reached $523000.0, down 95.02%, while the annual FY2024 figure was $526000.0, 41.56% down from the prior year.
- Receivables - Net reached $523000.0 in Q3 2025 per SGMO's latest filing, up from $372000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $10.5 million in Q3 2024 and bottomed at $366000.0 in Q1 2025.
- Average Receivables - Net over 5 years is $3.9 million, with a median of $3.7 million recorded in 2022.
- Peak YoY movement for Receivables - Net: surged 814.29% in 2024, then tumbled 95.02% in 2025.
- A 5-year view of Receivables - Net shows it stood at $6.0 million in 2021, then crashed by 38.47% to $3.7 million in 2022, then plummeted by 75.68% to $900000.0 in 2023, then plummeted by 41.56% to $526000.0 in 2024, then fell by 0.57% to $523000.0 in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Net were $523000.0 in Q3 2025, $372000.0 in Q2 2025, and $366000.0 in Q1 2025.